Brussels, 26/04/2005 (Agence Europe) - At the end of last year, further to a request from the European Commission on 17 December 2004, the European Medicines Agency launched review of antidepressants and especially of serotonin-selective reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor medicines. All such substances (atomoxatine, citalopram, duloxetine,, escitalopram, fluoxetine, fluvoxamine, mianserine, milnacepran, mirtazapine, paroxetine, reboxetine, sertraline and...